top of page


Onco-Summaries: Daily Oncology Updates at a Glance
29/09/2025 In an ~$8B deal, Genmab will acquire Merus in an all-cash transaction ( Ref ) Genmab and Merus announced a transaction...
Oncofocus Team
Sep 29, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
25/09/2025 Eli Lilly and Company's Inluriyo has been approved in the US for ER+, HER2–, ESR1-mutated breast cancer ( Ref ) The US FDA...
Oncofocus Team
Sep 26, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
24/09/2025 AstraZeneca and Daiichi's trastuzumab deruxtecan + pertuzumab received priority review status for first-line HER2+ve breast...
Oncofocus Team
Sep 25, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
23/09/2025 Kelun Biotech's NDA for A400/EP0031 in RET +ve NSCLC was accepted by China's NMPA ( Ref ) China's NMPA has accepted Sichuan...
Oncofocus Team
Sep 24, 20252 min read


Onco-Summaries: Daily Oncology Updates at a Glance
22/09/2025 Nuvalent completed the NDA submission to the FDA for zidesamtinib in ROS +ve NSCLC ( Ref ) Nuvalent, Inc has completed its NDA...
Oncofocus Team
Sep 24, 20251 min read


Onco-Summaries: Daily Oncology Updates at a Glance
19/09/2025 Merck & Co/MSD received positive EU CHMP Opinions for perioperative pembrolizumab regimen in SCCHN, and for subcutaneous...
Oncofocus Team
Sep 24, 20252 min read
bottom of page
.png)